AdAlta Nears First FDA Advice for Cancer Therapy as Australian Manufacturing Plans Advance
Closing price · 2026-10-26: $0.003 · +0.00%
AdAlta says the FDA has accepted a pre-IND meeting request for its EW-001 cancer therapy, with advice expected to guide testing and proposed clinical-trial plans; initial Australian manufacturing runs are targeted for the second half of 2026. The company also reported that the first complete responder has passed two years without cancer recurrence, EW-001 received special-access approval in China’s Hainan province, and it received an R&D tax refund, with further funding expected in the December quarter.